Sandbox Reserved 1490: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 22: | Line 22: | ||
[[Image:controlANG.png]] | [[Image:controlANG.png]] | ||
''Fig 1. These cells express Tie2 and are marked with GFP. They were incubated with vehicle (control; left column) and COMP–Ang1 (right column). The scale bars represent 10 μm.''<ref>PMID:19223473</ref> | ''Fig 1. These cells express Tie2 and are marked with GFP. They were incubated with vehicle (control; left column) and COMP–Ang1 (right column). The scale bars represent 10 μm.''<ref>PMID:19223473</ref> | ||
| Line 222: | Line 223: | ||
[[Image:Venous Malformations Diagram.jpg]] | [[Image:Venous Malformations Diagram.jpg]] | ||
''Fig 4. Diagram : Comparison of the Kinase Activities of Normal and Mutant TIE2 Receptors. (B) Cells infected with wild-type baculovirus (wt) or virus expressing normal TIE2 (R2) or mutant TIE2 (W2). Cells expressing the mutation at position 849 (Arginine → Tryptophan) have an autophosphorylation activity 6 to 10 times higher than wild cells.''<ref>PMID:8980225</ref> | ''Fig 4. Diagram : Comparison of the Kinase Activities of Normal and Mutant TIE2 Receptors. (B) Cells infected with wild-type baculovirus (wt) or virus expressing normal TIE2 (R2) or mutant TIE2 (W2). Cells expressing the mutation at position 849 (Arginine → Tryptophan) have an autophosphorylation activity 6 to 10 times higher than wild cells.''<ref>PMID:8980225</ref> | ||
| Line 228: | Line 230: | ||
[[Image:Venous Malformations Immunohistochemistry.jpg]] | [[Image:Venous Malformations Immunohistochemistry.jpg]] | ||
''Fig 5. Pictures of immunohistochemistry of VMs with Antibodies against Smooth Muscle Cells 𝛂-Actin <ref>PMID:8980225</ref>'' | ''Fig 5. Pictures of immunohistochemistry of VMs with Antibodies against Smooth Muscle Cells 𝛂-Actin <ref>PMID:8980225</ref>'' | ||
| Line 269: | Line 272: | ||
[[Image:electro.png]] | [[Image:electro.png]] | ||
''Fig 6. Western blot of p-TIE2 in Human Endothelial Cells transfected with TIE2-WT (Wild type) or with mutant TIE2 (L914F). Tubulin served as loading control. The hyperphosphorylation is clearly visible.''<ref>PMID:26258417</ref> | ''Fig 6. Western blot of p-TIE2 in Human Endothelial Cells transfected with TIE2-WT (Wild type) or with mutant TIE2 (L914F). Tubulin served as loading control. The hyperphosphorylation is clearly visible.''<ref>PMID:26258417</ref> | ||
| Line 276: | Line 280: | ||
[[Image:lesion area.png]] | [[Image:lesion area.png]] | ||
''Fig 7. (C) HUVECs lesional area measured every 2 days for 16 days. (D) Vascular volume at day 15 measured by analysis of color Doppler 3D image stacks. When compared with the vehicle-treated group, the lesional area was significantly smaller in the rapamycin-treated group from day 4 to day 16 and in the TIE2-TKI–treated group from day 8 to day 14.''<ref>PMID:26258417</ref> | ''Fig 7. (C) HUVECs lesional area measured every 2 days for 16 days. (D) Vascular volume at day 15 measured by analysis of color Doppler 3D image stacks. When compared with the vehicle-treated group, the lesional area was significantly smaller in the rapamycin-treated group from day 4 to day 16 and in the TIE2-TKI–treated group from day 8 to day 14.''<ref>PMID:26258417</ref> | ||
